Month: May 2020

CALGARY, Alberta, May 13, 2020 (GLOBE NEWSWIRE) — PrairieSky Royalty Ltd. (“PrairieSky” or the “Company“) (TSX: PSK) is pleased to announce that the Toronto Stock Exchange (the “TSX“) has accepted the notice of PrairieSky’s intention to commence a normal course issuer bid (the “NCIB“). PrairieSky previously purchased an aggregate of 1,335,700 common shares at a weighted average price per share of $13.30 under a normal course issuer bid that ran between May 13, 2019 and May 12, 2020.On April 20, 2020, PrairieSky announced its intention to seek TSX approval to renew its NCIB for an additional one-year period. The NCIB allows the Company to purchase up to 11,600,000 common shares (representing approximately 5.0% of the common shares outstanding of 232,426,991 as of May 5, 2020 and...

DALLAS, Texas, May 13, 2020 (GLOBE NEWSWIRE) — Capital Southwest Corporation (“Capital Southwest” or the “Company”; Nasdaq: CSWC), an internally managed business development company focused on providing flexible financing solutions to support the acquisition and growth of middle market businesses, announced today that it will release its fourth quarter and fiscal year 2020 results on Monday, June 1, 2020 after the market closes.  In conjunction with the release, Capital Southwest has scheduled a conference call which will be broadcast live via phone and over the Internet on Tuesday, June 2, 2020 at 11:00 a.m. Eastern time.  Investors may participate either by phone or audio webcast.By Phone:Dial (866)-502-8274 and provide the operator with Conference ID 2096883 at least 10 minutes before the call.  A replay of the conference call...

BOULDER, Colo., May 13, 2020 (GLOBE NEWSWIRE) — Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases, today announced financial results for the first quarter ended March 31, 2020 and provided a corporate update.“Brickell has continued to make progress during the first quarter of 2020, and we remain committed to advancing sofpironium bromide into Phase 3 clinical studies in the U.S.,” commented Robert Brown, Chief Executive Officer of Brickell. “As we continue to prepare for the initiation of our pivotal studies, we are encouraged by the top-line results of our recently completed Phase 3 long-term safety study.  Furthermore, the Japanese Phase 3 pivotal study data that...

CHICAGO, May 13, 2020 (GLOBE NEWSWIRE) — Tribune Publishing (NASDAQ:TPCO) today announced it will report its financial results for the first quarter on Friday, May 22, 2020.The Company will host a conference call to discuss its business and financial results at 8:30 a.m. Eastern time (7:30 a.m. Central time). The conference call may be accessed via Tribune Publishing’s Investor Relations website at investor.tribpub.com or by dialing 844.494.0195 (508.637.5599 for international callers) and entering conference ID 1045919. A replay of the webcast will also be available for one year on the Tribune Publishing website. To access the replay via telephone, dial 855.859.2056 (404.537.3406 for international callers), conference ID 1045919.About Tribune PublishingTribune Publishing (NASDAQ: TPCO) is a media company rooted in award-winning...

BIRMINGHAM, Mich., May 13, 2020 (GLOBE NEWSWIRE) — Conifer Holdings, Inc. (Nasdaq: CNFR) (“Conifer” or the “Company”) today announced results for the first quarter ended March 31, 2020.First Quarter 2020 Financial Highlights (compared to the prior year period)Gross written premium increased 3.6% to $25.1 million due to growth in commercial specialty linesCommercial Lines combined ratio was 112.8% (accident year combined ratio was 94.9%)Personal Lines combined ratio was 96.9% (accident year combined ratio was 92.9%)The Company’s overall combined ratio was 111.6% (accident year combined ratio was 94.7%)Net loss of $4.7 million, or $0.49 per share based on 9.6 million average shares outstanding; largely due to a decline in the fair value of equity securities resulting from disruption in financial markets related to the COVID-19 pandemicManagement...

All three patients in Cohort 3 now confirmed respondersAll three complete responders in the study remain clinically and metabolically stable after longer-term follow-upUltragenyx to host ASGCT recap investor conference call Friday, May 15 at 8:30 a.m. Eastern TimeNOVATO, Calif., May 13, 2020 (GLOBE NEWSWIRE) — Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for rare and ultra-rare diseases, today announced positive longer-term safety and efficacy data from the first three cohorts of the ongoing Phase 1/2 study of DTX301, an investigational adeno-associated virus (AAV) gene therapy for the treatment of ornithine transcarbamylase (OTC) deficiency. Six of nine patients in the study have responded to the gene therapy (three female, three male),...

WILMINGTON, Del., May 13, 2020 (GLOBE NEWSWIRE) — Acorn Energy, Inc. (OTCQB: ACFN), a provider of remote monitoring and control systems and IoT services for generators, pipelines, compressors and other industrial equipment through its OmniMetrix subsidiary, today announced results for its first quarter (Q1’20) ended March 31, 2020. Acorn will host an investor call tomorrow, May 14th at 11:00 a.m. ET to discuss its results and outlook (details below).Jan Loeb, Acorn’s CEO, commented, “Our Q1’20 topline and bottomline performance were relatively stable versus Q1’19, despite business development headwinds. Monitoring revenue rose 17% in Q1’20 but was offset by a 21% decrease in hardware sales, reflecting energy industry challenges and some business disruption from the Coronavirus pandemic. Q1’20 gross margin improved to 69%,...

Frisco, TX, May 13, 2020 (GLOBE NEWSWIRE) — Comstock Resources, Inc. (NYSE: CRK) (“Comstock” or the “Company”) announced today that it has commenced an underwritten public offering of 40 million shares of its common stock (the “Common Stock Offering”).  Comstock also intends to grant the underwriters a 30-day option to purchase up to 6 million additional shares of common stock.Comstock intends to use the net proceeds from the offering to redeem the Company’s Series A Redeemable Convertible Preferred Stock for $210 million plus accrued and unpaid dividends and to reduce amounts outstanding under its bank credit facility. Citigroup is acting as the sole book-running manager and representative of the underwriters for the offering.The offering of these securities is being made pursuant to an effective shelf registration statement. The...

NEW YORK, May 13, 2020 (GLOBE NEWSWIRE) — New York Mortgage Trust, Inc. (Nasdaq: NYMT) (the “Company”) is scheduled to report financial results for the three months ended March 31, 2020 after the close of market on May 21, 2020. New York Mortgage Trust’s executive management will host a conference call and audio webcast at 9:00 a.m., Eastern Time, on Friday, May 22, 2020. The conference call dial-in number is 877-312-8806.A live audio webcast of the conference call can be accessed via the Internet, on a listen-only basis, at the Investor Relations section of the Company’s website at www.nymtrust.com. Please allow extra time, prior to the call, to visit the site and download the necessary software to listen to the Internet broadcast.A replay of the conference call will be available by calling 855-859-2056. The conference...

SAN FRANCISCO, May 13, 2020 (GLOBE NEWSWIRE) — BridgeBio Pharma, Inc. (Nasdaq: BBIO), today reported its financial results for the first quarter ended March 31, 2020 and provided an update on the company’s operations.The company is working with its committed partners to minimize disruption from the COVID-19 pandemic on its clinical trials and other drug development programs. BridgeBio salutes the brave physicians, nurses, first responders and medical staff who are working across the globe to care for patients with COVID-19.BridgeBio’s fully enrolled trials and preclinical programs are moving ahead with minimal delays, and the company is on track to file its second New Drug Application (NDA) later this year, along with the anticipated filing of multiple investigational new drug applications (INDs). Despite the challenges presented...